Skip to content

Acute Myeloid Leukemia With Mutated Npm1 C2826177

Published: July 22, 2026Updated: August 20, 2026

A common genetic subtype of acute myeloid leukemia where the NPM1 gene is mutated, affecting how a protein controls cell growth. It occurs in adults and is often associated with a better prognosis, especially without other genetic changes. Standard chemotherapy is typically effective.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C92.A2, C92.A1, C92.62
ICD-11
2A00.0
Body system
hematologic
Severity
critical
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Symptoms may be severe and require urgent medical attention.

Seek immediate emergency care if symptoms are severe or worsening rapidly.

!

Sudden weakness

Fever

(hematologic)

Petechiae

(hematologic)

Night sweats

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Induction Chemotherapy with NPM1 Targeting

Standard intensive chemotherapy followed by consolidation, with particular attention to achieving molecular remission given favorable NPM1 mutation prognosis.

medication
2

Standard interventional procedure protocol

Requires immediate emergency medical intervention. Do not delay treatment.

procedure
3

Consolidation Chemotherapy

Additional intensive chemotherapy cycles after induction to consolidate remission and eliminate residual disease.

procedure

Additional treatment options

FLT3 Inhibitor Therapy

Targeted therapy for NPM1-mutated AML with concurrent FLT3 mutations, using inhibitors to enhance chemotherapy effectiveness.

medication

Molecular MRD Testing

Quantitative PCR monitoring of NPM1 mutation burden to detect molecular relapse before hematologic recurrence.

monitoring

Psychosocial Support Services

Counseling and support services addressing anxiety, depression, and coping challenges common during AML treatment and survivorship.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Acute Myeloid Leukemia With Mutated Npm1 C2826177?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms: Acute Myeloid Leukemia With NPM1 Mutation. Blood. 2022.

guideline2022
2

Döhner H, Wei AH, Löwenberg B. NPM1-mutated acute myeloid leukemia: current understanding and persistent controversies. Blood. 2021.

review2021
3

Kantarjian HM, Short NJ, Dinardo CD, et al. Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation for NPM1-mutated AML: A Phase II Clinical Trial. J Clin Oncol. 2023.

clinical_trial2023
4

Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognostic Implications of NPM1 Mutations in AML: A Meta-Analysis of 2500 Patients. N Engl J Med. 2020.

meta_analysis2020

Medication Comparisons

Compare medications used to treat Acute Myeloid Leukemia With Mutated Npm1 C2826177. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy